Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1996 Feb;87(2):200–205. doi: 10.1111/j.1349-7006.1996.tb03159.x

Therapeutic Drug Monitoring of Etoposide in a 14‐Day Infusion for Non‐small‐cell Lung Cancer

Yuichi Ando 1,2, Hironobu Minami 1, Hideo Saka 1, Masahiko Ando 2, Shuzo Sakai 2, Kaoru Shimokata 1,✉
PMCID: PMC5921058  PMID: 8609070

Abstract

We investigated whether a constant plasma concentration could be obtained by the individualized administration of low‐dose, prolonged‐infusional etoposide. Etoposide was infused for 14 days at 40 mg/m2day initially in patients with inoperable non‐small‐cell lung cancer. The infusion rate was modified based upon the etoposide concentration at 24 h following the initiation of the infusion (C24) to achieve a target concentration of 1.5 μg/ml. We postulated that severe toxicities could be avoided by maintaining the steady‐state concentration at less than 2 7mu;g/ml, while antitumor activity could be expected if the steady‐state concentration was maintained at more than 1 μg/ml. In a total of 21 courses in 12 patients, the mean etoposide dose was 35±6 mg/m2 daily. The C24 was 1.8±0.4 μg/ml and ranged from 1.1 to 2.9 μg/ml. Following dose modification, the mean concentration from 96 to 336 h (Cmean) was 1.6±0.2 μg/ml and ranged from 1.2 to 2.0 μg/ml. The toxicities were well‐tolerated except for one patient with WHO grade 4 leukopenia and neutropenia who developed infectious complications. There were no treatment‐related deaths. Following dose modification, the inter‐patient variability was decreased successfully. Although this pharmacologically‐guided method needs to be validated using more patients, it could be used for therapeutic drug monitoring.

Keywords: Etoposide, Low dose, Drug monitoring, Pharmacokinetics, Non‐small‐cell lung cancer

Full Text

The Full Text of this article is available as a PDF (411.3 KB).

REFERENCES

  • 1).Fleming , R. A. , Miller , A. A. and Stewart , C. F.Etoposide: an update . Clin. Pharm. 8 , 274 – 293 ( 1989. ). [PubMed] [Google Scholar]
  • 2).O'Dwyer , P. J. , Leyland‐Jones , B. , Alonso , M. T. , Marsoni , S. and Wittes , R. E.Etoposide (VP‐16‐213). Current status of an active anticancer drug . N. Engl. J. Med. 312 , 692 – 700 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 3).Radice , P. A. , Bunn , P. A. , Jr. and Ihde , D. C.Therapeutic trials with VP‐16‐213 and VM‐26: active agents in small cell lung cancer, non‐Hodgkin's lymphomas, and other malignancies . Cancer Treat. Rep. 63 , 1231 – 1237 ( 1979. ). [PubMed] [Google Scholar]
  • 4).Loike , J. D. and Horwitz , S. B.Effect of VP‐16‐213 on the intracellular degradation of DNA in HeLa cells . Biochemistry 15 , 5443 – 5448 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 5).Long , B. H. , Musial , S. T. and Brattain , M. G.Single‐ and double‐strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide . Cancer Res. 45 , 3106 – 3112 ( 1985. ). [PubMed] [Google Scholar]
  • 6).Drewinko , B. and Barlogie , B.Survival and cycle‐progression delay of human lymphoma cells in vitro exposed to VP‐16‐213 . Cancer Treat. Rep. 60 , 1295 – 1306 ( 1976. ). [PubMed] [Google Scholar]
  • 7).Dombernowsky , P. and Nissen , N. I.Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP 16‐213 (NSC‐141540) in L1210 leukemia . Acta Pathol. Microbiol Scand. [A] 81 , 715 – 724 ( 1973. ). [DOI] [PubMed] [Google Scholar]
  • 8).Roed , H. , Vindelov , L. L. , Christensen , I. J. , Spang Thomsen , M. and Hansen , H. H.The effect of the two epipodophyllotoxin derivatives etoposide (VP‐16) and teniposide (VM‐26) on cell lines established from patients with small cell carcinoma of the lung . Cancer Chemother. Pharmacol. 19 , 16 – 20 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 9).Wolff , S. N. , Grosh , W. W. , Prater , K. and Hande , K. R.In vitro pharmacodynamic evaluation of VP‐16‐213 and implications for chemotherapy . Cancer Chemother. Pharmacol. 19 , 246 – 249 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 10).Abratt , R. P. , Willcox , P. A. , de Groot , M. , Goodman , H. T. , Jansen , E. R. and Mame Salton , D. G.Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma . Eur. J. Cancer 27 , 28 – 30 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 11).Cavalli , F. , Sonntag , R. W. , Jungi , F. , Senn , H. J. and Brunner , K. W.VP‐16‐213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules . Cancer Treat. Rep. 62 , 473 – 475 ( 1978. ). [PubMed] [Google Scholar]
  • 12).Slevin , M. L. , Clark , P. I. , Joel , S. P. , Malik , S. , Osborne , R. J. , Gregory , W. M. , Lowe , D. G. , Reznek , R. H. and Wrigley , P. F. M.A randomized trial to evaluate the effect of schedule on the activity of etoposide in small‐cell lung cancer . J. Clin. Oncol. 7 , 1333 – 1340 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 13).Kunitoh , H. and Watanabe , K.Phase I/II and pharmacologic study of long‐term continuous infusion etoposide combined with cisplatin in patients with advanced non‐small‐cell lung cancer . J. Clin. Oncol. 12 , 83 – 89 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 14).Thompson , D. S. , Hainsworth , J. D. , Hande , K. R. , Holzmer , M. C. and Greco , F. A.Prolonged administration of low‐dose, infusional etoposide in patients with etoposide‐sensitive neoplasms: a phase I/II study . J. Clin. Oncol. 11 , 1322 – 1328 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 15).Minami , H. , Shimokata , K. , Saka , H. , Saito , H. , Ando , Y. , Senda , K. , Nomura , F. and Sakai , S.Phase I clinical and pharmacokinetic study of a 14‐day infusion of etoposide in patients with lung cancer . J. Clin. Oncol. 11 , 1602 – 1608 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 16).Clark , P. I. , Slevin , M. L. , Joel , S. P. , Osborne , R. J. , Talbot , D. I. , Johnson , P. W. M. , Reznek , R. , Masud , T. , Gregory , W. and Wrigley , P. F. M.A randomized trial of two etoposide schedules in small‐cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity . J. Clin. Oncol. 12 , 1427 – 1435 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 17).Greco , F. A.Chronic etoposide administration: overview of clinical experience . Cancer Treat. Rev. , 19 ( Suppl. c ), 35 – 45 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 18).Miller , A. A. , Tolley , E. A. , Niell , H. B. , Griffin , J. P. and Mauer , A. M.Pharmacodynamics of prolonged oral etoposide in patients with advanced non‐small‐cell lung cancer . J. Clin. Oncol. 11 , 1179 – 1188 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 19).Harvey , V. J. , Slevin , M. L. , Joel , S. P. , Smythe , M. M. , Johnston , A. and Wrigley , P. F. M.Variable bioavailability following repeated oral doses of etoposide . Eur. J. Cancer Clin. Oncol. 21 , 1315 – 1319 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 20).Slevin , M. L. , Joel , S. P. , Papamichael , D. , Smith , I. , Ellis , P. , Nicolson , M. , Woodhull , J. and Talbot , D. C.Therapeutic monitoring of infusional etoposide in previously untreated small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. , 13 , 133 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 21).Waits , T. M. , Johnson , D. H. , Hainsworth , J. D. , Hande , K. R. , Thomas , M. and Greco , F. A.Prolonged administration of oral etoposide in non‐small‐cell lung cancer: a phase II trial . J. Clin. Oncol. 10 , 292 – 296 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) “ WHO Handbook for Reporting Results of Cancer Treatment ,” Offset publication 48 ( 1979. ). World Health Organization; , Geneva . [Google Scholar]
  • 23).Ratain , M. J. , Schilsky , R. L. , Choi , K. E. , Guarnieri , C. , Grimmer , D. , Vogelzang , N. J. , Senekjian , E. and Liebner , M. A.Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability . Clin. Pharmacol. Ther. 45 , 226 – 233 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 24).Ratain , M. J. , Mick , R. , Schilsky , R. L. , Vogelzang , N. J. and Berezin , F.Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity . J. Clin. Oncol. 9 , 1480 – 1486 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 25).Yamaoka , K. , Tanaka , H. , Okumura , K. , Yasuhara , M. and Hori , R.An analysis program MULTI (ELS) based on extended nonlinear least squares method for microcomputers . J. Pharmacobiodyn. 9 , 161 – 173 ( 1986. ). [PubMed] [Google Scholar]
  • 26).Lam , F. C. , Hung , C. T. and Perrier , D. G.Estimation of variance for harmonic mean half‐lives . J. Pharm. Sci. 74 , 229 – 231 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 27).Stewart , C. F. , Arbuck , S. G. , Fleming , R. A. and Evans , W. E.Changes in the clearance of total and unbound etoposide in patients with liver dysfunction . J. Clin. Oncol. 8 , 1874 – 1879 ( 1990. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES